Abstract: Disclosed herein is a method for alleviating a chronic liver disease, comprising administrating to a subject in need thereof a pharmaceutical composition containing rosoxacin.

Abstract: The inventive concept provides a substrate treating apparatus. The substrate treating apparatus includes treating modules having an opening for taking in and taking out a substrate and which are stacked on each other; and an air flow generating member for generating a downward airflow at each treating module, and wherein the air flow generating member includes: a pan unit configured to supply an air; a spray unit configured to be provided above the treating module and which sprays an air supplied from the pan unit; and an exhaust unit configured to exhaust an air sprayed by the spray unit to outside of the treating module.

Abstract: Disclosed is a meta-structure. The meta-structure includes a lower electrode, a lower insulating layer on the lower electrode, a lower metal oxide layer on the lower insulating layer, a metal layer on the lower metal oxide layer, an upper metal oxide layer on the metal layer, an upper insulating layer on the upper metal oxide layer, and antenna electrodes on the upper insulating layer.

Abstract: Systems, methods, and instrumentalities are disclosed for phase noise reference signal (PNRS) transmission, comprising receiving, at a wireless transmit receive unit (WTRU), scheduling information for a Physical Uplink Shared Channel (PUSCH) transmission, wherein the scheduling information includes an indication of a set of physical resource blocks (PRBs) and a modulation coding scheme (MCS) level, determining a density for the PNRS transmission based on at least one of: the MCS level, a frequency band for the PUSCH transmission, or a subcarrier spacing of the PUSCH transmission, and transmitting the PUSCH in the scheduled set of PRBs using the determined density of PNRS.

Abstract: The present disclosure relates to an overcurrent protection inverter, and more particularly, to an inverter, which uses a leg-shunt resistor so as to detect an instantaneous maximum output current and an AD current, thereby performing an inverter protection operation. The present disclosure detects the instantaneous maximum output current and detects the AD current from the leg-shunt resistor so as to perform an overcurrent protection operation when an overcurrent occurs in the entire inverter operation section, thereby enabling protection of the inverter.

Abstract: A complementary thin film transistor (TFT) includes a substrate and a first TFT and a second TFT disposed on the substrate, wherein a first conductive semiconductor layer of the first TFT and a second gate electrode layer of the second TFT are disposed in the same layer and include the same material.

Abstract: Provided is a method of forming a micro/nanowire having a nanometer- to micrometer-sized diameter at predetermined positions of an object. The method includes: preparing a micro/nanopipette having a tip with an inner diameter which is substantially the same as the diameter of the micro/nanowire to be formed; filling the micro/nanopipette with a solution containing a micro/nanowire-forming material; brining the solution into contact with the object through the tip of the micro/nanopipette; and pulling the micro/nanopipette from the object at a pulling speed lower than or equal to a predetermined critical speed (?c) to obtain a micro/nanowire having substantially the same diameter as the inner diameter of the micro/nanopipette tip.

Abstract: Disclosed herein is a method for alleviating a chronic liver disease, comprising administrating to a subject in need thereof a pharmaceutical composition containing rosoxacin.

Abstract: Disclosed herein is a method against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The method includes administering to a subject in need thereof a first active ingredient selected from the group consisting of methotrexate (MIX) and a pharmaceutically acceptable salt thereof, and a second active ingredient selected from the group consisting of remdesivir and a pharmaceutically acceptable salt thereof. A molar ratio of the first active ingredient to the second active ingredient ranges from 1:13 to 1:25.

Abstract: Disclosed herein is a method against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The method includes administering to a subject in need thereof a first active ingredient selected from the group consisting of methotrexate (MIX) and a pharmaceutically acceptable salt thereof, and a second active ingredient selected from the group consisting of remdesivir and a pharmaceutically acceptable salt thereof. A molar ratio of the first active ingredient to the second active ingredient ranges from 1:13 to 1:25.

Abstract: A method for identifying a compound that inhibits an activity of a histone lysine demethylase, in which the compound interacts with three sites of a pocket of the histone lysine demethylase generated by using a computer program, an alpha-ketoglutarate (AKG), a methylated lysine, and a NIQ.

Abstract: Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.

Abstract: A method for treating cancer in a subject is provided; the method includes administrating bupropion to the subject, wherein the tumor cells of the cancer overexpress neuronal acetylcholine receptor subunit ?9 (CHRNA9). Another method for treating cancer in a subject is provided; the method includes administrating a pharmaceutical composition to the subject, wherein the pharmaceutical composition includes: a therapeutically effective amount of bupropion and a pharmaceutically acceptable excipient; wherein the tumor cells of the cancer overexpress CHRNA9. A method for inhibiting migration of tumor cells is also provided; the method includes administrating an effective amount of bupropion to the tumor cells; wherein the tumor cells overexpress CHRNA9.

Abstract: A method for identifying a compound that inhibits an activity of a histone lysine demethylase, in which the compound interacts with three sites of a pocket of the histone lysine demethylase generated by using a computer program, an alpha-ketoglutarate (AKG), a methylated lysine, and a NIQ.

Abstract: A preparation method for a magnetic composite for treating and diagnosing cancer. The method may include a step of pyrolyzing a precursor of a magnetic nanoparticle in the presence of a conjugated polymer. The preparation method for a magnetic composite can produce a magnetic composite economically and efficiently because a magnetic composite comprising a magnetic nanoparticle coated with a conjugated polymer can be prepared by a single process.

Abstract: The present invention relates to a method for identifying a compound that inhibits an activity of a histone lysine demethylase.

Abstract: Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.

Abstract: The present invention provides a compound of formula (I) or the salt thereof: wherein R is at least one selected from the group consisting of unsubstituted C1-4 alkyl, C1-4 alkyl substituted by C6-18 aryl or —OR1, and —C(?O)Z. The compound is a type-S protein kinase inhibitor, which binds to an ATP-binding site and a substrate-recognition site of a protein kinase simultaneously. The present invention further provides a pharmaceutical composition, which includes a compound of formula (I) or a salt and a pharmaceutically acceptable carrier thereof. The present invention further provides a use of a compound of formula (I) or a salt thereof, which is for the manufacture of a protein kinase inhibitor as a drug.

Abstract: A preparation method for a magnetic composite for treating and diagnosing cancer. The method may include a step of pyrolyzing a precursor of a magnetic nanoparticle in the presence of a conjugated polymer. The preparation method for a magnetic composite can produce a magnetic composite economically and efficiently because a magnetic composite comprising a magnetic nanoparticle coated with a conjugated polymer can be prepared by a single process.

Abstract: The present invention provides a compound of Formula (I) and a salt thereof, wherein, m is an integer of 2 to 7, and R is independently at least one selected from the group consisting of hydrogen and C1-C20 alkyl. The compound promotes apoptosis in cancer cell and inhibits its growth. The present invention also provides a pharmaceutical composition which comprises the compound of Formula (I), a salt thereof and a pharmaceutically acceptable carrier. The present invention further provides a method for production of the pharmaceutical composition used for treating cancer.